High sensitivity, increased specificity, and
improved precision
for accurate
prediction of recurrence and
better stratification
of patients with
improved PFS over genomic-only
methods1,2
Enhanced Performance
Rapid Turnaround Time
9-day average turnaround time for MRD in the clinical setting3
MRD, molecular residual disease; PFS, progression-free survival.
Guardant Infinity is for Research Use Only. Not for use in diagnostic procedures.
QUANTIFY CANCER
Guardant Infinity enables liquid-only MRD and response monitoring that is accessible and scalable across clinical trials.
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma InfinityAI for BioPharma
Tissue-Free Sampling
A simple blood draw making it significantly easier to acquire, enabling a higher evaluable rate for clinical studies